Ultralife (ULBI) Financials

Ultralife logo
$15.58 -0.11 (-0.70%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$15.54 -0.04 (-0.24%)
As of 11/20/2026 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Ultralife

Annual Income Statements for Ultralife

This table shows Ultralife's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
2.87 3.51 7.65 25 5.21 5.23 -0.23 -0.12 7.20 6.31 -5.90
Consolidated Net Income / (Loss)
2.84 3.48 7.66 25 5.31 5.33 -0.23 -0.12 7.17 6.41 -5.95
Net Income / (Loss) Continuing Operations
2.84 3.48 7.66 25 5.31 5.33 -0.23 -0.12 7.17 6.41 -5.95
Total Pre-Tax Income
3.15 3.58 6.30 6.61 6.77 7.02 -0.15 -0.45 9.12 8.30 -8.40
Total Operating Income
3.33 3.76 6.48 6.56 7.37 5.70 0.04 0.13 9.48 9.97 -5.90
Total Gross Profit
23 25 26 26 31 29 25 29 39 42 46
Total Revenue
76 82 86 87 107 108 98 132 159 164 191
Operating Revenue
76 82 86 87 107 108 98 132 159 164 191
Total Cost of Revenue
53 57 59 62 76 79 74 102 119 122 145
Operating Cost of Revenue
53 57 59 62 76 79 74 102 119 122 145
Total Operating Expenses
20 21 20 19 24 23 25 29 30 32 52
Selling, General & Admin Expense
14 15 15 15 17 18 18 22 22 24 29
Research & Development Expense
5.60 5.95 4.74 4.51 6.81 5.95 6.83 7.08 7.53 8.27 10
Impairment Charge
0.15 - - - - - - - - 0.00 12
Total Other Income / (Expense), net
-0.18 -0.18 -0.18 0.06 -0.60 1.32 -0.19 -0.58 -0.36 -1.66 -2.50
Interest Expense
0.25 0.26 0.18 0.06 0.54 0.44 0.24 0.95 2.02 1.94 3.95
Other Income / (Expense), net
0.07 0.08 0.00 0.12 -0.06 1.76 0.06 0.38 1.66 0.28 1.46
Income Tax Expense
0.31 0.10 -1.37 -18 1.46 1.69 0.08 -0.33 1.95 1.89 -2.45
Net Income / (Loss) Attributable to Noncontrolling Interest
-0.03 -0.03 0.02 0.07 0.11 0.10 0.00 -0.00 -0.03 0.10 -0.05
Basic Earnings per Share
$0.18 $0.23 $0.49 $1.57 $33.00 $0.33 $0.05 $0.05 $0.44 $38.00 ($35.00)
Weighted Average Basic Shares Outstanding
16.18M 15.26M 15.53M 15.88M 15.78M 15.90M 16.04M 16.13M 16.21M 16.56M 16.64M
Diluted Earnings per Share
$0.17 $0.23 $0.48 $1.53 $32.00 $0.33 $0.05 $0.05 $0.44 $38.00 ($35.00)
Weighted Average Diluted Shares Outstanding
16.46M 15.41M 15.86M 16.35M 16.18M 16.10M 16.04M 16.13M 16.23M 16.77M 16.64M
Weighted Average Basic & Diluted Shares Outstanding
15.32M 15.36M 15.60M 15.66M 15.87M 15.96M 16.13M 16.14M 16.45M 16.63M 16.66M

Quarterly Income Statements for Ultralife

This table shows Ultralife's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
2.89 2.97 0.26 0.19 1.87 0.88 -1.22 -7.42 -0.45 2.54 2.37
Consolidated Net Income / (Loss)
2.90 2.99 0.28 0.23 1.88 0.87 -1.25 -7.45 -0.47 2.52 2.38
Net Income / (Loss) Continuing Operations
2.90 2.99 0.28 0.23 1.88 0.87 -1.25 -7.45 -0.47 2.52 2.38
Total Pre-Tax Income
3.61 3.85 0.35 0.50 2.45 1.11 -1.75 -10 -0.66 2.99 2.75
Total Operating Income
4.06 3.92 0.51 1.47 3.40 2.26 -0.95 -11 -0.22 3.44 3.19
Total Gross Profit
11 12 8.68 11 13 12 9.62 12 10 14 13
Total Revenue
42 43 36 44 51 49 43 48 47 48 48
Operating Revenue
42 43 36 44 51 49 43 48 47 48 48
Total Cost of Revenue
30 31 27 33 38 37 34 36 37 34 35
Operating Cost of Revenue
30 31 27 33 38 37 34 36 37 34 35
Total Operating Expenses
7.41 7.65 8.17 9.13 9.35 9.35 11 23 10 10 10
Selling, General & Admin Expense
5.65 5.65 6.07 6.71 6.94 7.03 7.72 7.66 7.36 7.20 6.92
Research & Development Expense
1.76 2.00 2.10 2.41 2.40 2.32 2.86 2.82 2.96 3.23 3.19
Total Other Income / (Expense), net
-0.46 -0.07 -0.16 -0.98 -0.95 -1.14 -0.80 0.40 -0.45 -0.45 -0.44
Interest Expense
0.52 0.42 0.17 0.83 1.03 0.99 0.99 0.94 0.87 0.84 0.92
Other Income / (Expense), net
0.06 0.35 0.02 -0.15 0.08 -0.15 0.19 1.34 0.42 0.39 0.48
Income Tax Expense
0.70 0.85 0.07 0.26 0.57 0.24 -0.50 -2.75 -0.19 0.47 0.36
Net Income / (Loss) Attributable to Noncontrolling Interest
0.01 0.02 0.02 0.04 0.01 -0.01 -0.03 -0.03 -0.02 -0.03 0.02
Basic Earnings per Share
$0.08 $0.18 $0.02 $37.72 $11.00 $5.00 ($0.07) ($35.00) ($3.00) $15.00 $0.14
Weighted Average Basic Shares Outstanding
16.40M 16.57M 16.63M 16.56M 16.63M 16.64M 16.65M 16.64M 16.66M 16.66M 16.66M
Diluted Earnings per Share
$0.08 $0.18 $0.02 $37.72 $11.00 $5.00 ($0.07) ($35.00) ($3.00) $15.00 $0.14
Weighted Average Diluted Shares Outstanding
16.52M 16.83M 16.87M 16.77M 16.68M 16.66M 16.65M 16.64M 16.66M 16.71M 16.70M
Weighted Average Basic & Diluted Shares Outstanding
16.47M 16.62M 16.63M 16.63M 16.63M 16.64M 16.65M 16.66M 16.66M 16.66M 16.67M

Annual Cash Flow Statements for Ultralife

This table details how cash moves in and out of Ultralife's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-3.32 -3.76 7.28 7.60 -19 3.25 -2.24 -2.70 4.57 -3.42 2.49
Net Cash From Operating Activities
8.55 7.65 7.27 11 -2.97 22 4.33 -1.26 1.93 17 11
Net Cash From Continuing Operating Activities
8.55 7.65 7.27 11 -2.97 22 4.33 -1.26 1.93 17 11
Net Income / (Loss) Continuing Operations
2.84 3.48 7.66 25 5.31 5.33 -0.23 -0.12 7.17 6.41 -5.95
Consolidated Net Income / (Loss)
2.84 3.48 7.66 25 5.31 5.33 -0.23 -0.12 7.17 6.41 -5.95
Depreciation Expense
2.40 2.22 2.01 1.97 2.22 2.34 2.91 3.18 3.02 3.13 3.98
Amortization Expense
0.31 0.57 0.47 0.43 0.57 0.65 0.74 1.32 0.95 1.12 1.78
Non-Cash Adjustments To Reconcile Net Income
0.81 0.72 0.65 1.73 1.88 -0.65 0.67 0.78 0.53 0.86 13
Changes in Operating Assets and Liabilities, net
2.19 0.66 -3.53 -18 -13 14 0.24 -6.41 -9.74 5.12 -1.94
Net Cash From Investing Activities
-2.91 -11 -1.39 -4.19 -32 -2.98 -26 -1.68 -2.55 -50 -3.87
Net Cash From Continuing Investing Activities
-2.91 -11 -1.39 -4.19 -32 -2.98 -26 -1.68 -2.55 -50 -3.87
Purchase of Property, Plant & Equipment
-2.91 -1.22 -1.39 -4.19 -6.28 -3.10 -2.81 -1.68 -2.55 -1.93 -3.87
Acquisitions
0.00 -9.86 - 0.00 -25 0.00 -24 - 0.00 -48 0.00
Net Cash From Financing Activities
-8.87 -0.18 1.40 1.17 16 -16 20 0.52 5.49 30 -4.68
Net Cash From Continuing Financing Activities
-8.87 -0.18 1.40 1.17 16 -16 20 0.52 5.49 30 -4.68
Repayment of Debt
0.00 -3.03 - 0.00 -1.02 -16 -1.59 -2.93 -3.00 -27 -0.02
Issuance of Debt
0.00 3.03 - 0.00 18 - 21 3.35 7.25 55 -4.75
Other Financing Activities, net
0.52 0.43 1.40 1.91 0.92 0.15 0.25 0.10 1.24 2.00 0.10
Other Net Changes in Cash
- - - -0.27 -0.15 0.20 - - - 0.03 0.05
Cash Interest Paid
0.15 0.18 0.10 0.13 0.58 0.38 0.14 0.93 1.96 1.86 3.69
Cash Income Taxes Paid
0.05 0.27 0.35 0.22 0.27 0.26 0.32 0.35 0.77 0.72 0.15

Quarterly Cash Flow Statements for Ultralife

This table details how cash moves in and out of Ultralife's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-0.18 -3.41 0.08 0.08 1.87 2.22 -1.68 0.09 -0.46 -2.23 1.97
Net Cash From Operating Activities
-0.08 8.93 4.75 3.05 3.37 5.94 0.20 1.49 2.26 1.19 -2.93
Net Cash From Continuing Operating Activities
-0.08 8.93 4.75 3.05 3.37 5.94 0.20 1.49 2.26 1.18 -2.94
Net Income / (Loss) Continuing Operations
2.90 2.99 0.28 0.23 1.88 0.87 -1.25 -7.45 -0.47 2.52 2.38
Consolidated Net Income / (Loss)
2.90 2.99 0.28 0.23 1.88 0.87 -1.25 -7.45 -0.47 2.52 2.38
Depreciation Expense
0.74 0.79 0.77 0.83 0.95 1.01 1.01 1.02 1.05 1.06 1.10
Amortization Expense
0.24 0.24 0.24 0.40 0.47 0.48 0.48 0.36 0.33 0.32 0.33
Non-Cash Adjustments To Reconcile Net Income
0.16 0.16 0.17 0.37 0.23 0.24 0.36 12 -0.00 0.09 0.09
Changes in Operating Assets and Liabilities, net
-4.13 4.74 3.29 1.22 -0.16 3.34 -0.40 -4.73 1.34 -2.81 -6.84
Net Cash From Investing Activities
-0.37 -0.36 -0.59 -49 -0.90 -1.10 -0.99 -0.89 -0.77 -0.45 -0.59
Net Cash From Continuing Investing Activities
-0.37 -0.36 -0.59 -49 -0.90 -1.10 -0.99 -0.89 -0.77 -0.45 -0.59
Purchase of Property, Plant & Equipment
-0.37 -0.36 -0.59 -0.61 -0.90 -1.10 -1.00 -0.88 -0.77 -0.45 -0.59
Net Cash From Financing Activities
0.19 -12 -4.08 46 -0.69 -2.65 -0.65 -0.69 -2.06 -3.03 5.88
Net Cash From Continuing Financing Activities
0.19 -12 -4.08 46 -0.69 -2.65 -0.65 -0.69 -2.06 -3.03 5.88
Repayment of Debt
- - -0.07 -27 - 0.66 - - -2.06 2.06 -8.75
Issuance of Debt
-0.50 -13 -4.03 73 -0.69 - -0.69 -0.69 - - 15
Other Financing Activities, net
0.69 1.25 0.02 0.04 - 0.06 0.04 - - - 0.01
Other Net Changes in Cash
- - - -0.02 0.08 - - - 0.12 0.06 -0.39

Annual Balance Sheets for Ultralife

This table presents Ultralife's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
82 85 97 121 145 138 160 168 178 220 217
Total Current Assets
52 49 62 67 70 64 67 79 90 97 106
Cash & Equivalents
14 11 18 26 7.41 11 8.41 5.71 10 6.85 9.35
Accounts Receivable
11 13 15 16 30 21 20 28 32 29 34
Inventories, net
24 23 26 23 30 28 33 41 42 51 54
Prepaid Expenses
1.90 2.08 2.60 2.37 3.10 4.60 4.69 4.30 5.95 9.57 8.50
Plant, Property, & Equipment, net
9.04 8.00 7.57 11 23 23 23 22 21 40 40
Total Noncurrent Assets
21 27 28 43 52 50 70 68 67 83 71
Goodwill
16 20 20 20 27 27 38 37 38 45 45
Intangible Assets
3.95 7.19 7.09 6.50 9.72 9.21 17 16 15 25 11
Noncurrent Deferred & Refundable Income Taxes
- 0.09 0.03 15 13 12 11 12 11 8.41 10
Other Noncurrent Operating Assets
0.31 0.07 0.13 0.89 1.96 2.29 2.88 2.31 3.71 4.83 3.91
Total Liabilities & Shareholders' Equity
82 85 97 121 145 138 160 168 178 220 217
Total Liabilities
16 17 18 16 35 21 42 52 53 86 87
Total Current Liabilities
11 11 14 15 17 19 19 29 24 29 37
Short-Term Debt
- - - 0.00 1.37 1.36 2.00 2.00 2.00 2.75 4.13
Accounts Payable
6.49 7.29 8.79 9.92 9.39 11 9.82 16 11 14 17
Current Employee Benefit Liabilities
2.38 1.26 2.41 1.49 1.66 1.75 1.84 2.89 3.12 2.91 2.75
Other Current Liabilities
1.75 2.61 2.87 3.97 4.78 4.76 5.26 7.95 7.28 9.47 13
Total Noncurrent Liabilities
4.66 5.56 3.90 1.00 18 2.07 23 23 29 57 49
Long-Term Debt
- - - 0.00 16 0.00 19 19 24 52 46
Noncurrent Deferred & Payable Income Tax Liabilities
4.63 5.54 3.87 0.59 0.56 0.52 2.25 1.92 1.71 1.44 1.00
Other Noncurrent Operating Liabilities
0.03 0.02 0.03 0.41 1.28 1.56 1.76 1.89 3.78 4.03 2.92
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
66 68 79 104 110 117 118 116 125 134 130
Total Preferred & Common Equity
66 68 79 105 110 117 118 116 125 134 130
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
66 68 79 105 110 117 118 116 125 134 130
Common Stock
179 180 182 185 186 188 189 189 191 194 195
Retained Earnings
-94 -91 -83 -58 -53 -48 -48 -48 -41 -34 -40
Treasury Stock
-18 -18 -18 -19 -21 -21 -21 -21 -21 -21 -21
Accumulated Other Comprehensive Income / (Loss)
-0.91 -3.08 -1.61 -2.79 -2.53 -1.78 -1.65 -3.75 -3.66 -4.01 -3.14
Noncontrolling Interest
-0.14 -0.17 -0.15 -0.09 0.02 0.12 0.13 0.13 0.10 0.19 0.14

Quarterly Balance Sheets for Ultralife

This table presents Ultralife's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
176 181 170 172 224 221 222 221 216 224
Total Current Assets
90 94 84 86 101 99 101 110 107 117
Cash & Equivalents
9.30 10 6.69 6.77 8.72 11 9.26 8.89 6.66 8.63
Accounts Receivable
27 35 31 28 36 32 31 34 35 36
Inventories, net
47 44 41 44 48 51 53 57 59 62
Prepaid Expenses
6.43 5.10 4.65 7.91 8.84 5.17 7.68 9.50 6.98 9.91
Plant, Property, & Equipment, net
21 21 20 20 40 41 41 40 40 39
Total Noncurrent Assets
65 66 66 66 82 81 81 70 69 69
Goodwill
37 37 38 38 45 45 45 45 45 45
Intangible Assets
15 15 15 14 24 24 23 11 10 10
Noncurrent Deferred & Refundable Income Taxes
11 9.87 9.09 9.13 8.02 7.69 8.21 11 10 10
Other Noncurrent Operating Assets
2.04 3.34 4.51 4.36 4.66 4.41 4.14 3.67 3.40 3.19
Total Liabilities & Shareholders' Equity
176 181 170 172 224 221 222 221 216 224
Total Liabilities
54 52 36 38 87 82 85 91 84 90
Total Current Liabilities
26 23 21 26 31 30 34 43 37 39
Short-Term Debt
2.00 2.00 2.00 2.00 3.09 3.44 3.78 3.44 1.75 3.13
Accounts Payable
13 13 9.69 13 17 15 14 24 23 20
Current Employee Benefit Liabilities
2.47 2.01 2.31 2.63 3.21 2.67 2.94 2.85 2.93 2.94
Other Current Liabilities
8.45 6.05 6.57 8.89 8.58 8.76 13 13 10 14
Total Noncurrent Liabilities
28 28 16 12 56 52 51 48 46 50
Long-Term Debt
24 23 9.98 5.89 51 48 47 44 43 47
Noncurrent Deferred & Payable Income Tax Liabilities
1.83 1.68 1.64 1.63 1.41 1.40 1.36 0.97 0.93 0.90
Other Noncurrent Operating Liabilities
2.03 3.42 4.28 4.09 3.73 3.51 3.24 2.68 2.41 2.16
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
122 129 133 135 137 139 137 130 133 135
Total Preferred & Common Equity
122 129 133 134 136 138 137 130 133 135
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
122 129 133 134 136 138 137 130 133 135
Common Stock
191 192 193 194 194 194 195 195 195 195
Retained Earnings
-44 -38 -35 -35 -33 -32 -33 -41 -38 -36
Treasury Stock
-21 -21 -21 -21 -21 -21 -21 -21 -21 -21
Accumulated Other Comprehensive Income / (Loss)
-4.18 -3.89 -3.90 -3.08 -3.70 -2.82 -3.06 -3.06 -2.85 -3.29
Noncontrolling Interest
0.12 0.11 0.13 0.15 0.21 0.20 0.17 0.12 0.09 0.11

Annual Metrics And Ratios for Ultralife

This table displays calculated financial ratios and metrics derived from Ultralife's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
15,219,620.00 15,235,246.00 15,627,513.00 15,956,677.00 15,856,907.00 15,928,055.00 16,080,749.00 16,133,618.00 16,340,113.00 16,626,930.00 16,648,947.00
DEI Adjusted Shares Outstanding
15,219,620.00 15,235,246.00 15,627,513.00 15,956,677.00 15,856,907.00 15,928,055.00 16,080,749.00 16,133,618.00 16,340,113.00 16,626,930.00 16,648,947.00
DEI Earnings Per Adjusted Shares Outstanding
0.19 0.23 0.49 1.56 0.33 0.33 -0.01 -0.01 0.44 0.38 -0.35
Growth Metrics
- - - - - - - - - - -
Revenue Growth
14.94% 7.89% 3.72% 1.94% 22.49% 0.86% -8.77% 34.17% 20.33% 3.66% 16.24%
EBITDA Growth
297.27% 8.82% 34.89% 1.38% 11.21% 3.43% -64.25% 33.90% 202.16% -4.10% -90.90%
EBIT Growth
312.59% 13.20% 68.57% 3.06% 9.50% 2.04% -98.78% 454.95% 2,104.55% -8.01% -143.40%
NOPAT Growth
397.23% 21.91% 115.42% 214.29% -76.66% -25.16% -99.43% 268.57% 8,147.39% 3.31% -153.70%
Net Income Growth
233.27% 22.61% 120.10% 226.19% -78.74% 0.32% -104.31% 47.83% 6,071.67% -10.56% -192.85%
EPS Growth
0.00% 35.29% 108.70% 218.75% 1,991.50% -98.97% -84.85% 0.00% 780.00% 8,536.36% -192.11%
Operating Cash Flow Growth
133.32% -10.50% -5.00% 49.74% -127.28% 831.31% -80.09% -129.20% 252.73% 762.42% -33.94%
Free Cash Flow Firm Growth
165.20% -136.13% 314.79% 61.36% -604.83% 146.02% -239.14% 92.35% 23.05% -2,398.34% 121.18%
Invested Capital Growth
-4.74% 11.02% 6.24% 29.33% 52.17% -9.93% 20.96% 1.39% 6.65% 28.99% -6.14%
Revenue Q/Q Growth
-0.90% 2.96% 1.05% -1.78% 10.44% -1.87% -5.04% 10.33% 5.62% -0.42% 2.48%
EBITDA Q/Q Growth
-6.98% 19.77% 4.70% -9.66% 16.95% 4.67% -51.68% 37.10% 31.53% -12.72% -88.79%
EBIT Q/Q Growth
-12.00% 41.86% 7.07% -12.55% 20.21% 7.80% -97.87% 167.88% 49.60% -18.70% -172.30%
NOPAT Q/Q Growth
-12.05% 51.90% 35.81% 173.52% -76.20% -18.35% -98.69% 109.80% 69.42% -23.33% -188.77%
Net Income Q/Q Growth
-11.14% 55.86% 36.88% 176.23% -77.30% 9.35% -107.63% 88.27% 75.17% -28.99% -443.00%
EPS Q/Q Growth
0.00% 64.29% 33.33% 178.18% 50.66% -98.97% 100.32% 101.25% 214.29% 6,451.72% -35,100.00%
Operating Cash Flow Q/Q Growth
-19.24% 63.14% -6.10% -2.32% -99.06% -7.05% -50.24% 84.14% -6.40% 3.83% -12.41%
Free Cash Flow Firm Q/Q Growth
-33.78% 71.13% -25.17% -21.44% -6.59% -14.13% -929.69% 94.46% -28.67% -357.58% 118.42%
Invested Capital Q/Q Growth
2.05% -4.46% 1.45% 30.79% 1.83% 3.70% 26.46% -0.86% 1.59% 33.77% -4.50%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
30.51% 30.45% 30.67% 29.34% 29.18% 27.07% 25.08% 22.30% 24.71% 25.73% 24.07%
EBITDA Margin
7.98% 8.05% 10.47% 10.42% 9.46% 9.70% 3.80% 3.79% 9.52% 8.81% 0.69%
Operating Margin
4.36% 4.56% 7.57% 7.52% 6.90% 5.29% 0.04% 0.10% 5.97% 6.06% -3.09%
EBIT Margin
4.44% 4.66% 7.57% 7.66% 6.84% 6.92% 0.09% 0.38% 7.02% 6.23% -2.33%
Profit (Net Income) Margin
3.72% 4.22% 8.96% 28.67% 4.98% 4.95% -0.23% -0.09% 4.52% 3.90% -3.11%
Tax Burden Percent
90.16% 97.26% 121.75% 378.03% 78.48% 75.91% 152.32% 26.91% 78.60% 77.21% 70.86%
Interest Burden Percent
92.78% 93.16% 97.18% 99.06% 92.63% 94.15% -165.93% -88.32% 81.89% 81.06% 188.93%
Effective Tax Rate
9.84% 2.74% -21.75% -278.03% 21.52% 24.09% 0.00% 0.00% 21.40% 22.79% 0.00%
Return on Invested Capital (ROIC)
5.69% 6.74% 13.38% 35.59% 5.84% 3.81% 0.02% 0.07% 5.46% 4.77% -2.35%
ROIC Less NNEP Spread (ROIC-NNEP)
6.69% 8.15% 14.90% 34.60% 11.63% 444.91% -16.13% -1.43% 3.64% 0.68% -6.50%
Return on Net Nonoperating Assets (RNNOA)
-1.57% -1.54% -2.94% -8.35% -0.88% 0.89% -0.22% -0.17% 0.47% 0.16% -2.16%
Return on Equity (ROE)
4.12% 5.20% 10.43% 27.25% 4.96% 4.70% -0.20% -0.10% 5.93% 4.94% -4.50%
Cash Return on Invested Capital (CROIC)
10.55% -3.70% 7.33% 10.01% -35.54% 14.26% -18.95% -1.31% -0.97% -20.55% 3.98%
Operating Return on Assets (OROA)
4.01% 4.62% 7.12% 6.12% 5.51% 5.29% 0.06% 0.31% 6.42% 5.14% -2.03%
Return on Assets (ROA)
3.36% 4.19% 8.43% 22.93% 4.00% 3.78% -0.15% -0.07% 4.13% 3.21% -2.72%
Return on Common Equity (ROCE)
4.13% 5.21% 10.46% 27.28% 4.96% 4.70% -0.20% -0.10% 5.92% 4.93% -4.50%
Return on Equity Simple (ROE_SIMPLE)
4.29% 5.12% 9.68% 23.91% 4.84% 4.56% -0.20% -0.10% 5.72% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
3.00 3.66 7.88 25 5.78 4.33 0.02 0.09 7.45 7.69 -4.13
NOPAT Margin
3.93% 4.44% 9.22% 28.42% 5.41% 4.02% 0.02% 0.07% 4.69% 4.68% -2.16%
Net Nonoperating Expense Percent (NNEP)
-1.00% -1.41% -1.52% 0.99% -5.79% -441.10% 16.15% 1.50% 1.82% 4.10% 4.15%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 4.93% 4.08% -2.30%
Cost of Revenue to Revenue
69.49% 69.55% 69.33% 70.66% 70.82% 72.93% 74.92% 77.70% 75.29% 74.27% 75.93%
SG&A Expenses to Revenue
18.62% 18.67% 17.56% 16.65% 15.91% 16.26% 18.09% 16.83% 13.99% 14.64% 15.35%
R&D to Revenue
7.33% 7.21% 5.54% 5.17% 6.37% 5.52% 6.95% 5.37% 4.75% 5.03% 5.44%
Operating Expenses to Revenue
26.15% 25.89% 23.10% 21.82% 22.28% 21.78% 25.04% 22.20% 18.74% 19.67% 27.16%
Earnings before Interest and Taxes (EBIT)
3.40 3.84 6.48 6.68 7.31 7.46 0.09 0.51 11 10 -4.45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
6.10 6.64 8.96 9.08 10 10 3.73 5.00 15 14 1.32
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.49 1.11 1.29 1.03 1.07 0.88 0.83 0.54 0.89 0.92 0.73
Price to Tangible Book Value (P/TBV)
2.14 1.85 1.98 1.38 1.60 1.28 1.56 0.99 1.53 1.92 1.29
Price to Revenue (P/Rev)
1.29 0.91 1.20 1.24 1.10 0.96 0.99 0.47 0.70 0.75 0.50
Price to Earnings (P/E)
34.27 21.49 13.38 4.32 22.51 19.70 0.00 0.00 15.48 19.62 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
2.92% 4.65% 7.47% 23.15% 4.44% 5.08% 0.00% 0.00% 6.46% 5.10% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.62 1.13 1.38 1.04 1.06 0.87 0.84 0.59 0.90 0.94 0.80
Enterprise Value to Revenue (EV/Rev)
1.09 0.78 0.98 0.94 1.19 0.87 1.12 0.59 0.80 1.04 0.71
Enterprise Value to EBITDA (EV/EBITDA)
13.71 9.72 9.36 9.00 12.57 8.99 29.38 15.60 8.40 11.83 102.86
Enterprise Value to EBIT (EV/EBIT)
24.64 16.79 12.95 12.24 17.37 12.59 1,205.48 154.45 11.40 16.74 0.00
Enterprise Value to NOPAT (EV/NOPAT)
27.86 17.63 10.64 3.30 21.95 21.70 4,477.50 863.77 17.04 22.29 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
9.78 8.43 11.54 7.50 0.00 4.32 25.36 0.00 65.78 10.31 12.35
Enterprise Value to Free Cash Flow (EV/FCFF)
15.03 0.00 19.42 11.72 0.00 5.80 0.00 0.00 0.00 0.00 19.34
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.16 0.01 0.18 0.18 0.20 0.40 0.38
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.14 0.00 0.16 0.17 0.19 0.38 0.35
Financial Leverage
-0.23 -0.19 -0.20 -0.24 -0.08 0.00 0.01 0.12 0.13 0.24 0.33
Leverage Ratio
1.23 1.24 1.24 1.19 1.24 1.25 1.27 1.40 1.43 1.54 1.65
Compound Leverage Factor
1.14 1.16 1.20 1.18 1.15 1.17 -2.10 -1.24 1.17 1.24 3.13
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 13.52% 1.15% 15.05% 15.47% 16.96% 28.79% 27.62%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 1.08% 1.15% 1.44% 1.45% 1.32% 1.46% 2.29%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 12.43% 0.00% 13.61% 14.02% 15.64% 27.33% 25.32%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-0.22% -0.25% -0.19% -0.08% 0.02% 0.10% 0.09% 0.09% 0.06% 0.10% 0.08%
Common Equity to Total Capital
100.22% 100.25% 100.19% 100.08% 86.47% 98.75% 84.86% 84.43% 82.97% 71.11% 72.31%
Debt to EBITDA
0.00 0.00 0.00 0.00 1.70 0.13 5.59 4.26 1.70 3.74 37.64
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.97 -0.89 3.33 3.12 1.02 3.27 30.56
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 1.56 0.00 5.05 3.86 1.56 3.55 34.52
Debt to NOPAT
0.00 0.00 0.00 0.00 2.97 0.31 851.31 235.99 3.44 7.05 -12.02
Net Debt to NOPAT
0.00 0.00 0.00 0.00 1.69 -2.15 507.92 172.72 2.06 6.16 -9.76
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 2.73 0.00 769.67 213.84 3.17 6.69 -11.02
Altman Z-Score
3.87 2.85 3.88 4.69 2.86 3.85 1.95 1.47 2.49 1.91 1.59
Noncontrolling Interest Sharing Ratio
-0.19% -0.23% -0.22% -0.13% -0.03% 0.06% 0.11% 0.11% 0.09% 0.11% 0.13%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.79 4.36 4.35 4.37 4.09 3.45 3.52 2.73 3.80 3.32 2.83
Quick Ratio
2.38 2.10 2.31 2.73 2.18 1.70 1.51 1.16 1.77 1.24 1.16
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
5.57 -2.01 4.32 6.97 -35 16 -23 -1.72 -1.33 -33 7.01
Operating Cash Flow to CapEx
293.85% 627.81% 522.27% 260.12% -47.29% 728.61% 153.70% -75.22% 75.59% 861.08% 283.83%
Free Cash Flow to Firm to Interest Expense
22.44 -7.65 23.60 110.63 -65.28 37.14 -93.11 -1.81 -0.66 -17.07 1.77
Operating Cash Flow to Interest Expense
34.48 29.10 39.73 172.79 -5.51 49.82 17.87 -1.33 0.96 8.58 2.78
Operating Cash Flow Less CapEx to Interest Expense
22.75 24.46 32.12 106.37 -17.16 42.98 6.24 -3.09 -0.31 7.58 1.80
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.90 0.99 0.94 0.80 0.80 0.76 0.66 0.80 0.92 0.82 0.87
Accounts Receivable Turnover
6.73 6.70 6.15 5.69 4.63 4.21 4.76 5.49 5.33 5.38 6.04
Inventory Turnover
2.13 2.43 2.38 2.51 2.88 2.71 2.40 2.75 2.86 2.61 2.75
Fixed Asset Turnover
0.00 9.68 10.99 9.52 6.42 4.75 4.27 5.87 7.41 5.34 4.73
Accounts Payable Turnover
7.87 8.32 7.38 6.59 7.83 7.77 7.13 7.91 8.72 9.58 9.19
Days Sales Outstanding (DSO)
54.27 54.46 59.39 64.20 78.82 86.68 76.68 66.46 68.49 67.84 60.45
Days Inventory Outstanding (DIO)
171.47 150.42 153.21 145.65 126.93 134.64 152.15 132.51 127.44 139.82 132.50
Days Payable Outstanding (DPO)
46.35 43.87 49.49 55.41 46.59 46.99 51.22 46.14 41.88 38.10 39.71
Cash Conversion Cycle (CCC)
179.38 161.01 163.12 154.44 159.16 174.33 177.61 152.84 154.05 169.56 153.23
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
51 57 61 79 119 108 130 132 141 182 170
Invested Capital Turnover
1.45 1.52 1.45 1.25 1.08 0.95 0.83 1.01 1.16 1.02 1.09
Increase / (Decrease) in Invested Capital
-2.56 5.67 3.57 18 41 -12 23 1.81 8.77 41 -11
Enterprise Value (EV)
84 65 84 82 127 94 110 78 127 171 136
Market Capitalization
98 75 102 108 117 103 97 62 111 124 95
Book Value per Share
$4.35 $4.47 $5.07 $6.55 $6.92 $7.33 $7.31 $7.21 $7.67 $8.06 $7.81
Tangible Book Value per Share
$3.02 $2.68 $3.31 $4.88 $4.62 $5.06 $3.87 $3.90 $4.45 $3.88 $4.43
Total Capital
66 68 79 104 127 118 139 138 151 188 180
Total Debt
0.00 0.00 0.00 0.00 17 1.36 21 21 26 54 50
Total Long-Term Debt
0.00 0.00 0.00 0.00 16 0.00 19 19 24 52 46
Net Debt
-15 -11 -18 -26 9.75 -9.29 12 16 15 47 40
Capital Expenditures (CapEx)
2.91 1.22 1.39 4.19 6.28 2.98 2.81 1.68 2.55 1.93 3.87
Debt-free, Cash-free Net Working Capital (DFCFNWC)
27 27 29 26 47 36 41 46 58 64 63
Debt-free Net Working Capital (DFNWC)
41 38 48 52 55 47 50 52 68 71 73
Net Working Capital (NWC)
41 38 48 52 53 46 48 50 66 68 68
Net Nonoperating Expense (NNE)
0.16 0.18 0.22 -0.22 0.47 -1.00 0.25 0.21 0.28 1.28 1.82
Net Nonoperating Obligations (NNO)
-15 -11 -18 -26 9.75 -9.29 12 16 15 47 40
Total Depreciation and Amortization (D&A)
2.71 2.80 2.48 2.41 2.79 2.99 3.64 4.50 3.98 4.25 5.76
Debt-free, Cash-free Net Working Capital to Revenue
34.76% 33.21% 34.31% 29.64% 44.15% 33.88% 41.91% 35.17% 36.68% 38.77% 33.09%
Debt-free Net Working Capital to Revenue
53.78% 46.19% 55.74% 59.38% 51.08% 43.78% 50.47% 39.50% 43.16% 42.94% 37.98%
Net Working Capital to Revenue
53.78% 46.19% 55.74% 59.38% 49.80% 42.51% 48.44% 37.98% 41.90% 41.27% 35.82%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.18 $0.23 $0.49 $1.57 $0.33 $33.00 ($0.01) $0.03 $0.03 $0.38 ($35.00)
Adjusted Weighted Average Basic Shares Outstanding
16.18M 15.26M 15.53M 15.88M 15.78M 15.90M 16.04K 16.13M 16.21M 16.56M 16.64M
Adjusted Diluted Earnings per Share
$0.00 $0.23 $0.48 $1.53 $0.32 $33.00 ($0.01) $0.03 $0.03 $0.38 ($35.00)
Adjusted Weighted Average Diluted Shares Outstanding
16.46M 15.41M 15.86M 16.35M 16.18M 16.10M 16.04K 16.13M 16.23M 16.77M 16.64M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
15.32M 15.36M 15.65M 20.06M 15.87M 15.96M 16.13M 16.14M 16.45M 16.63M 16.66M
Normalized Net Operating Profit after Tax (NOPAT)
3.14 3.66 4.53 4.59 5.78 4.33 0.02 0.09 7.45 7.69 4.40
Normalized NOPAT Margin
4.11% 4.44% 5.30% 5.26% 5.41% 4.02% 0.02% 0.07% 4.69% 4.68% 2.30%
Pre Tax Income Margin
4.12% 4.34% 7.36% 7.58% 6.34% 6.52% -0.15% -0.34% 5.75% 5.05% -4.39%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
13.69 14.61 35.40 105.97 13.56 17.11 0.38 0.53 5.52 5.28 -1.12
NOPAT to Interest Expense
12.11 13.92 43.08 393.33 10.73 9.93 0.10 0.10 3.69 3.97 -1.05
EBIT Less CapEx to Interest Expense
1.96 9.98 27.79 39.54 1.91 10.27 -11.25 -1.23 4.26 4.28 -2.10
NOPAT Less CapEx to Interest Expense
0.37 9.28 35.48 326.90 -0.92 3.09 -11.53 -1.67 2.43 2.97 -2.02
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
330.56% 17.43% 0.00% 2.97% 36.83% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Ultralife

This table displays calculated financial ratios and metrics derived from Ultralife's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
16,446,832.00 16,466,594.00 16,623,347.00 16,626,930.00 16,632,965.00 16,632,965.00 16,643,614.00 16,648,947.00 16,656,503.00 16,656,669.00 16,663,269.00
DEI Adjusted Shares Outstanding
16,446,832.00 16,466,594.00 16,623,347.00 16,626,930.00 16,632,965.00 16,632,965.00 16,643,614.00 16,648,947.00 16,656,503.00 16,656,669.00 16,663,269.00
DEI Earnings Per Adjusted Shares Outstanding
0.18 0.18 0.02 0.01 0.11 0.05 -0.07 -0.45 -0.03 0.15 0.14
Growth Metrics
- - - - - - - - - - -
Revenue Growth
31.37% 0.68% -9.61% -1.56% 21.03% 12.98% 21.51% 10.56% -6.50% -1.27% 11.30%
EBITDA Growth
441.99% -14.11% -54.10% -45.29% -4.17% -32.19% -52.61% -409.65% -67.50% 47.45% 632.66%
EBIT Growth
9,479.55% -17.41% -77.47% -64.01% -15.73% -50.63% -244.30% -800.08% -94.11% 81.71% 583.00%
NOPAT Growth
17,873.22% 17.33% -74.61% -79.23% -20.18% -42.15% -264.83% -1,170.04% -105.76% 64.35% 515.48%
Net Income Growth
966.87% -10.60% -78.59% -91.82% -35.30% -70.93% -546.95% -3,298.71% -125.07% 189.43% 291.10%
EPS Growth
166.67% 500.00% -75.00% 12,473.33% 13,650.00% -72.22% -450.00% -192.79% -127.27% 200.00% 300.00%
Operating Cash Flow Growth
94.07% 409.71% 633.86% 25.25% 4,258.02% -33.50% -95.83% -51.12% -33.02% -79.98% -1,580.30%
Free Cash Flow Firm Growth
-1,928.04% 441.18% 184.11% -638.51% -413.88% -8,615.37% -1,445.21% 109.27% 136.84% 128.78% 110.86%
Invested Capital Growth
7.51% 1.91% -2.04% 28.99% 26.05% 28.87% 31.48% -6.14% -7.17% -4.54% -1.09%
Revenue Q/Q Growth
-5.88% 2.52% -16.96% 22.86% 15.72% -4.31% -10.69% 11.78% -2.14% 1.05% 0.68%
EBITDA Q/Q Growth
9.65% 3.62% -71.07% 66.45% 92.08% -26.68% -79.78% -1,187.60% 120.16% 226.95% -2.17%
EBIT Q/Q Growth
12.18% 3.32% -87.66% 151.71% 162.69% -39.48% -136.06% -1,121.21% 102.21% 1,765.85% -4.16%
NOPAT Q/Q Growth
-2.08% -6.81% -86.75% 71.79% 276.33% -32.46% -137.75% -1,015.25% 97.97% 2,025.79% -4.57%
Net Income Q/Q Growth
1.89% 3.06% -90.68% -16.49% 706.44% -53.70% -243.33% -497.67% 93.68% 634.61% -5.36%
EPS Q/Q Growth
-73.33% 125.00% -88.89% 188,500.00% -70.84% 150.00% -240.00% -49,900.00% 91.43% 600.00% -99.07%
Operating Cash Flow Q/Q Growth
-103.33% 11,118.52% -46.82% -35.82% 10.57% 76.22% -96.66% 652.02% 51.51% -47.34% -346.72%
Free Cash Flow Firm Q/Q Growth
-24.99% 106.62% 618.05% -1,343.64% 13.03% -9.64% -13.43% 108.57% 245.50% -14.37% -57.21%
Invested Capital Q/Q Growth
2.28% -3.72% -2.08% 33.77% -0.05% -1.56% -0.10% -4.50% -1.15% 1.22% 3.51%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
27.36% 26.90% 24.32% 24.17% 25.12% 23.89% 22.18% 24.87% 21.31% 28.92% 27.54%
EBITDA Margin
12.19% 12.32% 4.29% 5.82% 9.65% 7.39% 1.67% -16.29% 3.36% 10.86% 10.55%
Operating Margin
9.69% 9.11% 1.43% 3.36% 6.70% 4.65% -2.19% -21.88% -0.45% 7.17% 6.60%
EBIT Margin
9.84% 9.92% 1.47% 3.02% 6.85% 4.33% -1.75% -19.12% 0.43% 7.98% 7.59%
Profit (Net Income) Margin
6.93% 6.96% 0.78% 0.53% 3.70% 1.79% -2.88% -15.37% -0.99% 5.25% 4.94%
Tax Burden Percent
80.51% 77.82% 79.04% 47.07% 76.82% 78.17% 71.22% 73.03% 71.04% 84.33% 86.81%
Interest Burden Percent
87.40% 90.20% 67.11% 37.39% 70.33% 52.87% 230.70% 110.11% -323.41% 78.07% 74.88%
Effective Tax Rate
19.49% 22.18% 20.96% 52.93% 23.18% 21.83% 0.00% 0.00% 0.00% 15.67% 13.19%
Return on Invested Capital (ROIC)
9.47% 8.72% 1.36% 1.61% 5.48% 4.09% -1.82% -16.63% -0.34% 6.48% 6.20%
ROIC Less NNEP Spread (ROIC-NNEP)
7.21% 8.21% -0.03% 0.15% 3.04% 0.15% -4.58% -16.70% -1.11% 5.51% 5.28%
Return on Net Nonoperating Assets (RNNOA)
0.96% 0.70% 0.00% 0.04% 0.69% 0.02% -0.71% -5.54% -0.35% 1.58% 1.61%
Return on Equity (ROE)
10.43% 9.43% 1.36% 1.65% 6.16% 4.12% -2.53% -22.17% -0.69% 8.07% 7.81%
Cash Return on Invested Capital (CROIC)
0.43% 6.29% 9.37% -20.55% -18.74% -21.66% -24.23% 3.98% 3.63% 1.30% -0.56%
Operating Return on Assets (OROA)
9.44% 9.71% 1.40% 2.49% 5.87% 3.97% -1.65% -16.71% 0.37% 6.84% 6.53%
Return on Assets (ROA)
6.64% 6.82% 0.74% 0.44% 3.17% 1.64% -2.72% -13.44% -0.84% 4.50% 4.25%
Return on Common Equity (ROCE)
10.42% 9.42% 1.36% 1.65% 6.16% 4.11% -2.53% -22.14% -0.69% 8.06% 7.80%
Return on Equity Simple (ROE_SIMPLE)
8.08% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
3.27 3.05 0.40 0.69 2.61 1.76 -0.67 -7.42 -0.15 2.90 2.77
NOPAT Margin
7.80% 7.09% 1.13% 1.58% 5.15% 3.63% -1.53% -15.31% -0.32% 6.05% 5.73%
Net Nonoperating Expense Percent (NNEP)
2.25% 0.51% 1.39% 1.47% 2.44% 3.95% 2.76% 0.07% 0.77% 0.98% 0.92%
Return On Investment Capital (ROIC_SIMPLE)
2.12% 2.10% 0.28% 0.37% 1.37% 0.93% -0.35% -4.13% -0.08% 1.64% 1.49%
Cost of Revenue to Revenue
72.64% 73.10% 75.68% 75.83% 74.88% 76.11% 77.82% 75.13% 78.69% 71.08% 72.46%
SG&A Expenses to Revenue
13.48% 13.14% 17.01% 15.30% 13.68% 14.47% 17.79% 15.80% 15.52% 15.03% 14.33%
R&D to Revenue
4.19% 4.65% 5.89% 5.50% 4.74% 4.77% 6.58% 5.82% 6.24% 6.73% 6.61%
Operating Expenses to Revenue
17.67% 17.79% 22.89% 20.81% 18.42% 19.24% 24.37% 46.74% 21.76% 21.75% 20.94%
Earnings before Interest and Taxes (EBIT)
4.13 4.26 0.53 1.32 3.48 2.11 -0.76 -9.27 0.21 3.83 3.67
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
5.11 5.30 1.53 2.55 4.90 3.59 0.73 -7.90 1.59 5.21 5.09
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.12 1.31 1.12 0.92 0.66 1.08 0.83 0.73 0.84 0.79 0.80
Price to Tangible Book Value (P/TBV)
1.89 2.16 1.83 1.92 1.33 2.16 1.66 1.29 1.47 1.37 1.36
Price to Revenue (P/Rev)
0.86 1.04 0.91 0.75 0.52 0.84 0.61 0.50 0.58 0.56 0.56
Price to Earnings (P/E)
13.89 17.38 16.71 19.62 16.92 46.73 66.07 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
7.20% 5.75% 5.98% 5.10% 5.91% 2.14% 1.51% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
1.11 1.30 1.12 0.94 0.74 1.06 0.87 0.80 0.88 0.84 0.85
Enterprise Value to Revenue (EV/Rev)
0.95 1.07 0.92 1.04 0.78 1.06 0.83 0.71 0.78 0.77 0.78
Enterprise Value to EBITDA (EV/EBITDA)
8.30 9.80 9.13 11.83 9.42 15.08 13.15 102.86 0.00 0.00 36.63
Enterprise Value to EBIT (EV/EBIT)
10.46 12.52 12.03 16.74 14.03 25.50 25.17 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
15.02 16.05 15.10 22.29 19.18 33.53 33.24 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
49.81 17.36 9.46 10.31 6.70 11.09 12.33 12.35 14.93 27.93 74.75
Enterprise Value to Free Cash Flow (EV/FCFF)
268.35 20.88 11.79 0.00 0.00 0.00 0.00 19.34 23.24 62.98 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.20 0.09 0.06 0.40 0.39 0.37 0.37 0.38 0.37 0.34 0.38
Long-Term Debt to Equity
0.18 0.07 0.04 0.38 0.37 0.34 0.34 0.35 0.34 0.32 0.35
Financial Leverage
0.13 0.09 0.07 0.24 0.23 0.17 0.15 0.33 0.31 0.29 0.30
Leverage Ratio
1.43 1.36 1.36 1.54 1.52 1.44 1.45 1.65 1.67 1.61 1.64
Compound Leverage Factor
1.25 1.23 0.91 0.57 1.07 0.76 3.35 1.82 -5.40 1.26 1.23
Debt to Total Capital
16.32% 8.24% 5.53% 28.79% 28.18% 26.87% 26.79% 27.62% 26.85% 25.17% 27.28%
Short-Term Debt to Total Capital
1.30% 1.38% 1.40% 1.46% 1.63% 1.81% 2.01% 2.29% 1.94% 0.99% 1.69%
Long-Term Debt to Total Capital
15.02% 6.87% 4.13% 27.33% 26.56% 25.06% 24.78% 25.32% 24.91% 24.18% 25.60%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.07% 0.09% 0.11% 0.10% 0.11% 0.10% 0.09% 0.08% 0.07% 0.05% 0.06%
Common Equity to Total Capital
83.61% 91.67% 94.36% 71.11% 71.71% 73.02% 73.12% 72.31% 73.08% 74.78% 72.66%
Debt to EBITDA
1.30 0.65 0.48 3.74 3.75 4.05 4.28 37.64 -23.97 -142.96 12.37
Net Debt to EBITDA
0.78 0.29 0.07 3.27 3.14 3.18 3.49 30.56 -19.50 -121.61 10.25
Long-Term Debt to EBITDA
1.20 0.54 0.35 3.55 3.54 3.78 3.95 34.52 -22.24 -137.35 11.60
Debt to NOPAT
2.36 1.07 0.79 7.05 7.64 9.01 10.81 -12.02 -7.15 -7.64 -17.19
Net Debt to NOPAT
1.41 0.47 0.11 6.16 6.40 7.08 8.82 -9.76 -5.82 -6.50 -14.26
Long-Term Debt to NOPAT
2.17 0.89 0.59 6.69 7.20 8.40 9.99 -11.02 -6.63 -7.34 -16.13
Altman Z-Score
2.87 4.11 3.49 1.78 1.61 2.10 1.79 1.52 1.68 1.82 1.82
Noncontrolling Interest Sharing Ratio
0.10% 0.11% 0.11% 0.11% 0.12% 0.12% 0.12% 0.13% 0.12% 0.11% 0.10%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
4.03 4.07 3.30 3.32 3.22 3.31 2.99 2.83 2.56 2.87 2.97
Quick Ratio
1.94 1.83 1.32 1.24 1.42 1.45 1.19 1.16 1.01 1.11 1.13
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-6.79 0.45 3.23 -40 -35 -38 -43 3.72 13 11 4.71
Operating Cash Flow to CapEx
-21.77% 2,479.17% 798.99% 502.64% 376.31% 539.55% 19.90% 168.82% 292.99% 262.25% -495.94%
Free Cash Flow to Firm to Interest Expense
-13.06 1.07 18.65 -48.39 -33.81 -38.56 -43.74 3.97 14.81 13.12 5.11
Operating Cash Flow to Interest Expense
-0.16 21.35 27.43 3.67 3.26 5.98 0.20 1.59 2.60 1.42 -3.18
Operating Cash Flow Less CapEx to Interest Expense
-0.87 20.49 24.00 2.94 2.40 4.87 -0.80 0.65 1.71 0.88 -3.82
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.96 0.98 0.95 0.82 0.86 0.92 0.95 0.87 0.85 0.86 0.86
Accounts Receivable Turnover
5.65 5.66 6.01 5.38 4.86 5.64 6.36 6.04 5.33 5.58 5.76
Inventory Turnover
2.75 2.85 2.69 2.61 2.83 2.94 2.94 2.75 2.75 2.59 2.48
Fixed Asset Turnover
8.02 8.16 7.98 5.34 5.69 5.87 6.14 4.73 4.67 4.67 4.83
Accounts Payable Turnover
7.77 8.84 9.33 9.58 8.67 10.94 10.58 9.19 7.10 7.53 8.46
Days Sales Outstanding (DSO)
64.65 64.47 60.71 67.84 75.14 64.67 57.42 60.45 68.48 65.39 63.37
Days Inventory Outstanding (DIO)
132.61 127.95 135.53 139.82 129.01 124.12 124.36 132.50 132.81 140.91 147.03
Days Payable Outstanding (DPO)
47.00 41.31 39.11 38.10 42.12 33.36 34.51 39.71 51.38 48.50 43.12
Cash Conversion Cycle (CCC)
150.25 151.12 157.14 169.56 162.02 155.43 147.27 153.23 149.91 157.80 167.28
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
144 139 136 182 181 179 178 170 168 171 177
Invested Capital Turnover
1.21 1.23 1.20 1.02 1.06 1.13 1.19 1.09 1.07 1.07 1.08
Increase / (Decrease) in Invested Capital
10 2.60 -2.82 41 38 40 43 -11 -13 -8.11 -1.95
Enterprise Value (EV)
160 180 152 171 135 190 155 136 147 143 150
Market Capitalization
145 175 150 124 89 149 114 95 109 105 108
Book Value per Share
$7.83 $8.04 $8.09 $8.06 $8.20 $8.32 $8.25 $7.81 $7.78 $7.96 $8.07
Tangible Book Value per Share
$4.65 $4.89 $4.94 $3.88 $4.03 $4.16 $4.12 $4.43 $4.42 $4.61 $4.74
Total Capital
154 145 143 188 190 190 188 180 177 177 185
Total Debt
25 12 7.89 54 54 51 50 50 48 45 51
Total Long-Term Debt
23 9.98 5.89 52 51 48 47 46 44 43 47
Net Debt
15 5.29 1.11 47 45 40 41 40 39 38 42
Capital Expenditures (CapEx)
0.37 0.36 0.59 0.61 0.90 1.10 1.00 0.88 0.77 0.45 0.59
Debt-free, Cash-free Net Working Capital (DFCFNWC)
63 59 55 64 64 62 61 63 62 65 72
Debt-free Net Working Capital (DFNWC)
73 65 62 71 73 73 71 73 70 72 80
Net Working Capital (NWC)
71 63 60 68 70 69 67 68 67 70 77
Net Nonoperating Expense (NNE)
0.37 0.06 0.12 0.46 0.73 0.89 0.58 0.03 0.32 0.38 0.38
Net Nonoperating Obligations (NNO)
15 5.29 1.11 47 45 40 41 40 39 38 42
Total Depreciation and Amortization (D&A)
0.98 1.03 1.01 1.23 1.42 1.49 1.49 1.37 1.39 1.38 1.43
Debt-free, Cash-free Net Working Capital to Revenue
37.25% 34.64% 33.58% 38.77% 37.14% 34.44% 32.94% 33.09% 32.79% 34.66% 37.38%
Debt-free Net Working Capital to Revenue
43.24% 38.60% 37.68% 42.94% 42.17% 40.56% 37.90% 37.98% 37.52% 38.21% 41.87%
Net Working Capital to Revenue
42.05% 37.42% 36.47% 41.27% 40.38% 38.64% 35.88% 35.82% 35.69% 37.28% 40.24%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.21 $0.21 $0.02 $37.72 $0.02 $0.05 ($0.07) ($35.00) ($3.00) $15.00 $0.14
Adjusted Weighted Average Basic Shares Outstanding
16.40M 16.57M 16.63M 16.56M 16.63M 16.64M 16.65M 16.64M 16.66M 16.66M 16.66M
Adjusted Diluted Earnings per Share
$0.21 $0.21 $0.02 $37.72 $0.02 $0.05 ($0.07) ($35.00) ($3.00) $15.00 $0.14
Adjusted Weighted Average Diluted Shares Outstanding
16.52M 16.83M 16.87M 16.77M 16.68M 16.66M 16.65M 16.64M 16.66M 16.71M 16.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
16.47M 16.62M 16.63M 16.63M 16.63M 16.64M 16.65M 16.66M 16.66M 16.66M 16.67M
Normalized Net Operating Profit after Tax (NOPAT)
3.27 3.05 0.40 1.03 2.61 1.76 -0.67 -7.42 -0.15 2.90 2.77
Normalized NOPAT Margin
7.80% 7.09% 1.13% 2.35% 5.15% 3.63% -1.53% -15.31% -0.32% 6.05% 5.73%
Pre Tax Income Margin
8.60% 8.95% 0.99% 1.13% 4.82% 2.29% -4.04% -21.05% -1.40% 6.23% 5.69%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
7.94 10.20 3.04 1.60 3.37 2.12 -0.77 -9.89 0.24 4.56 3.98
NOPAT to Interest Expense
6.29 7.29 2.33 0.84 2.53 1.78 -0.67 -7.92 -0.17 3.45 3.00
EBIT Less CapEx to Interest Expense
7.22 9.34 -0.39 0.87 2.50 1.01 -1.77 -10.83 -0.65 4.02 3.34
NOPAT Less CapEx to Interest Expense
5.58 6.43 -1.10 0.11 1.66 0.67 -1.67 -8.86 -1.06 2.91 2.36
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Ultralife’s second-quarter 2026 results show a meaningful recovery in profitability, although cash generation and working-capital management remain important concerns. Revenue was $47.9 million, up slightly from $47.4 million in the first quarter but down from $48.6 million in the year-ago quarter. Compared with the $39.5 million reported in Q3 2023, however, the company’s revenue base remains higher.

  • Profitability improved sharply. Gross profit increased to $13.9 million in Q2 2026 from $10.1 million in Q1 and $11.6 million in Q2 2025. The gross margin expanded to approximately 28.9%, compared with 21.3% in Q1 and 23.9% in the year-ago quarter.
  • Ultralife returned to operating profitability. Operating income was $3.4 million in Q2 2026, compared with an operating loss of $215,000 in Q1 and a $10.6 million operating loss in Q4 2025.
  • Net income recovered. Net income attributable to common shareholders was $2.5 million in Q2 2026, reversing losses of $451,000 in Q1 2026 and $7.4 million in Q4 2025.
  • Debt levels have declined during 2026. Total short- and long-term debt fell to approximately $44.6 million at June 30, 2026, from $47.6 million at March 31 and $52.5 million at June 30, 2025. Interest expense also declined to $839,000 from $992,000 a year earlier.
  • The balance sheet remains equity-supported. Total equity and noncontrolling interests stood at $132.6 million, representing roughly 61% of total assets. Total liabilities also declined to $83.6 million from $90.9 million at the end of Q1 2026.
  • Revenue growth has moderated. Q2 2026 revenue was broadly stable sequentially but remained below the $50.7 million recorded in Q1 2025 and the $48.6 million recorded in Q2 2025. The recent improvement is therefore being driven more by margins and cost performance than by strong sales growth.
  • Operating cash flow weakened. Cash provided by operations fell to $1.2 million in Q2 2026 from $2.3 million in Q1 and $5.9 million in Q2 2025. Operating assets and liabilities used $2.8 million of cash during the latest quarter.
  • Cash balances continue to shrink. Cash and equivalents declined to $6.7 million at June 30, 2026, from $8.9 million at March 31 and $10.9 million a year earlier. The company reported a $2.2 million net decrease in cash during Q2, largely because of debt repayments and capital spending.
  • Inventory and receivables are tying up capital. Inventory increased to $58.7 million from $50.6 million a year earlier, while accounts receivable rose to $34.8 million from $32.3 million. These balances are significant relative to the company’s $47.9 million quarterly revenue and could pressure cash flow if they do not convert into sales and collections.
  • Ultralife still carries accumulated losses and sizable intangible assets. Retained earnings were negative $38.2 million, while goodwill and intangible assets totaled approximately $55.8 million. Although equity is positive, future earnings will need to remain consistent to strengthen retained earnings and support the carrying value of these assets.

Overall, Q2 2026 marked a substantial earnings improvement, supported by stronger gross margins, lower operating expenses relative to gross profit, and reduced debt. For investors, the key question is whether this margin recovery can continue while Ultralife converts elevated inventory and receivables into cash. The improving income statement is encouraging, but declining cash and uneven operating cash flow suggest that the turnaround is not yet fully established.

11/21/26 12:14 PM ETAI Generated. May Contain Errors.

Ultralife Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Ultralife's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Ultralife's net income appears to be on a downward trend, with a most recent value of -$5.95 million in 2025, compared with $2.84 million in 2015. The previous period was $6.41 million in 2024. See Ultralife's forecast for analyst expectations on what's next for the company.

Ultralife's total operating income in 2025 was -$5.90 million, based on the following breakdown:
  • Total Gross Profit: $46.02 million
  • Total Operating Expenses: $51.92 million

Over the last 10 years, Ultralife's total revenue changed from $76.43 million in 2015 to $191.16 million in 2025, a change of 150.1%.

In the past 12 quarters, Ultralife's cash and equivalents has ranged from $6.66 million in Q2 2026 to $10.94 million in Q2 2025, and is currently $8.63 million as of their latest financial filing in Q3 2026.

Ultralife had total debt of $49.65 million at the end of 2025, a 8.5% decrease from 2024, and none in 2015.

Over the last 10 years, Ultralife's book value per share changed from 4.35 in 2015 to 7.81 in 2025, a change of 79.6%.



Financial statements for NASDAQ:ULBI last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners